BML Inc (JP:4694)
:4694
Top Page
BML
(4694)
Select Model
Select Model
Rating:74Outperform
Price Target:
¥4,499.00
▲(17.93% Upside)
Action:ReiteratedDate:11/01/25
BML's strong financial performance and positive technical indicators are the primary drivers of its stock score. The company's robust balance sheet and profitability metrics provide a solid foundation, while technical analysis suggests a positive market trend. The valuation is reasonable, with a moderate P/E ratio and attractive dividend yield. However, declining revenue and fluctuating cash flow present potential risks.
Positive Factors
Profitability & Margins
Consistent gross and healthy net margins reflect durable cost control and pricing power in diagnostic services. Sustained margins support reinvestment, dividend capacity and resilience to cyclical pressure, making core earnings a reliable driver of long-term cash generation.
Negative Factors
Declining Revenue Trend
A multi-year revenue decline is structurally concerning: it constrains scale economics, limits reinvestment capacity and increases pressure on profitability. Unless reversed via new services, market share gains or pricing strategy, growth prospects and ROE may weaken over months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability & Margins
Consistent gross and healthy net margins reflect durable cost control and pricing power in diagnostic services. Sustained margins support reinvestment, dividend capacity and resilience to cyclical pressure, making core earnings a reliable driver of long-term cash generation.
Read all positive factors
BML (4694) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥150.15B
Dividend Yield3.34%
Average Volume (3M)54.09K
Price to Earnings (P/E)15.5
Beta (1Y)0.45
Revenue Growth5.90%
EPS Growth16.30%
CountryJP
Employees4,513
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)62.09
Shares Outstanding40,749,428
10 Day Avg. Volume38,460
30 Day Avg. Volume54,093
Financial Highlights & Ratios
PEG Ratio5.02
Price to Book (P/B)0.91
Price to Sales (P/S)0.82
P/FCF Ratio177.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,500.00Price Target Upside17.96% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)205.4
Revenue Forecast (FY)¥153.50B
BML Business Overview & Revenue Model
Company Description
BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis;...
How the Company Makes Money
null...
BML Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 145.63B | 143.19B | 137.96B | 159.46B | 186.07B | 138.57B |
| Gross Profit | 46.42B | 45.86B | 45.63B | 61.45B | 86.95B | 54.77B |
| EBITDA | 17.84B | 17.08B | 15.96B | 30.29B | 54.78B | 25.39B |
| Net Income | 6.42B | 6.26B | 6.04B | 15.58B | 33.74B | 13.71B |
Balance Sheet | ||||||
| Total Assets | 175.54B | 177.99B | 171.46B | 169.27B | 179.59B | 142.76B |
| Cash, Cash Equivalents and Short-Term Investments | 65.46B | 67.56B | 74.11B | 86.52B | 92.13B | 63.48B |
| Total Debt | 4.29B | 5.29B | 5.26B | 4.16B | 3.35B | 4.21B |
| Total Liabilities | 42.81B | 44.21B | 41.32B | 42.52B | 57.91B | 49.64B |
| Stockholders Equity | 128.46B | 129.40B | 125.87B | 122.49B | 116.20B | 88.42B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 663.00M | -4.57B | 7.18B | 39.91B | 16.48B |
| Operating Cash Flow | 0.00 | 15.81B | 14.45B | 11.74B | 45.60B | 19.57B |
| Investing Cash Flow | 0.00 | -16.79B | -21.14B | -7.63B | -7.30B | -4.58B |
| Financing Cash Flow | 0.00 | -5.43B | -5.73B | -9.71B | -9.83B | -3.38B |
BML Technical Analysis
Neutral
3815.00
Price Trends
4023.54
Negative
3894.37
Positive
3666.84
Positive
Market Momentum
0.13
Positive
43.23
Neutral
31.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Neutral. The current price of 3815 is below the 20-day moving average (MA) of 4022.68, below the 50-day MA of 4023.54, and above the 200-day MA of 3666.84, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 43.23 is Neutral, neither overbought nor oversold. The STOCH value of 31.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4694.
BML Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥150.15B | 15.47 | 5.94% | 3.34% | 5.90% | 16.30% | |
74 Outperform | ¥63.07B | 14.39 | ― | 2.79% | 28.06% | 19.48% | |
68 Neutral | ¥113.08B | 26.70 | ― | 2.31% | 4.36% | 79.43% | |
52 Neutral | ¥137.39B | -8.84 | ― | 2.18% | -0.16% | -802.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥136.36B | 28.05 | 2.42% | 3.73% | 0.04% | ― |
* Healthcare Sector Average
JP:4694
BML
3,955.00
1,239.54
45.65%
JP:6523
PHC Holdings Corp.
1,076.00
179.36
20.00%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,515.00
292.19
23.89%
JP:4549
Eiken Chemical Co., Ltd.
3,465.00
1,371.00
65.47%
JP:4974
Takara Bio Inc.
1,141.00
360.00
46.09%
BML Corporate Events
BML Reshapes Leadership to Bolster Genome and Medical IT Businesses
Mar 30, 2026
BML, Inc. has announced a series of senior management and organizational changes approved by its Board of Directors on March 30, 2026, reflecting a strategic emphasis on genome-related services and systems operations. Representative Director and V...
BML Revises First-Quarter 2024 Earnings Data After Discovering Numerical Errors
Mar 16, 2026
BML, Inc. has announced corrections to its consolidated earnings report for the first quarter of fiscal 2024 under Japanese GAAP, after discovering errors in previously disclosed numerical data. The revisions mainly affect the company’s repo...
BML Corrects Third-Quarter 2024 Balance Sheet Figures and Equity Ratio
Mar 16, 2026
BML, Inc., a Japan-based clinical testing and diagnostic services provider listed on the Tokyo Prime Market, has issued a correction to its previously disclosed consolidated earnings report for the third quarter of fiscal 2024. The revision update...
BML Corrects Fiscal 2024 Earnings Report, Adjusts Asset and Profitability Ratios
Mar 16, 2026
BML, Inc. has announced corrections to its previously released consolidated earnings report for fiscal 2024, identifying and amending errors discovered after the original disclosure in May 2025. The revisions affect key profitability and balance s...
BML Revises First-Quarter FY2025 Balance-Sheet Figures, Lowers Reported Equity Ratio
Mar 16, 2026
BML, Inc. has corrected previously disclosed figures in its consolidated earnings report for the first quarter of fiscal 2025, released on August 8, 2025, after identifying errors in its financial position data. The revisions primarily affect repo...
BML Revises First-Half Fiscal 2025 Balance Sheet Figures After Data Errors
Mar 16, 2026
BML, Inc. announced it has corrected errors in its previously released consolidated earnings report for the first six months of fiscal 2025, adjusting key balance sheet figures while keeping equity capital unchanged. The revised data show total as...
BML Revises Third-Quarter Fiscal 2025 Balance Sheet Figures
Mar 16, 2026
BML, Inc. has corrected previously disclosed figures in its consolidated earnings report for the third quarter of fiscal 2025, revising total assets upward while leaving net assets unchanged. The company reported that total assets as of December 3...
BML Restates Five Years of Filings Over Retirement Benefit Accounting Error
Mar 16, 2026
BML, Inc. has submitted correction reports for past annual, semi-annual and quarterly securities filings, along with related earnings reports, after discovering errors in the accounting treatment of retirement benefit assets and liabilities. The c...
BML Raises Full-Year Earnings Forecast on New Customer Growth and Price Optimization
Feb 6, 2026
BML, Inc. has revised upward its consolidated earnings forecast for the fiscal year ending March 31, 2026, citing stronger-than-expected performance. The company now projects net sales of ¥149.0 billion, operating profit of ¥10.0 billion...
BML Delivers Strong Q3 Earnings and Raises Full-Year Outlook While Maintaining Dividend Plan
Feb 6, 2026
BML reported solid growth for the third quarter of fiscal 2025, with net sales rising 5.4% year-on-year to ¥114.5 billion and profit attributable to owners of the parent climbing 24.6% to ¥6.6 billion, reflecting improved profitability a...
BML Overhauls Shareholder Benefits to Reward Long-Term Investors
Jan 26, 2026
BML, Inc. has approved changes to its shareholder benefits program aimed at expressing gratitude to investors while making its shares more attractive for long-term ownership. Effective for shareholders of record as of March 31, 2027, the company w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.